Jazz Pharmaceuticals plc Stock
Price
Target price
€102.30
€102.30
1.850%
1.85
1.850%
€183.25
22:26 / Tradegate
WKN: A1JS1K / Symbol: JAZZ / Name: Jazz Pharma / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Jazz Pharmaceuticals plc Stock
Jazz Pharmaceuticals plc gained 1.850% today.
The stock is an absolute favorite of our community with 21 Buy predictions and no Sell predictions.
As a result the target price of 183 € shows a very positive potential of 78.89% compared to the current price of 102.3 € for Jazz Pharmaceuticals plc.
Pros and Cons of Jazz Pharmaceuticals plc in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Jazz Pharmaceuticals plc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Jazz Pharmaceuticals plc | 1.850% | -2.435% | -10.058% | -23.462% | -10.220% | -28.336% | -12.913% |
Opko Health Inc. | 1.930% | -0.982% | 23.925% | -16.662% | -19.340% | -68.292% | -43.684% |
Catalent Inc. | 0.330% | -0.744% | 0.038% | 34.767% | 26.262% | -45.242% | 51.485% |
Repligen Corp. | -1.120% | 4.675% | -9.437% | 13.270% | -7.816% | -14.357% | - |
Comments
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at JPMorgan Chase & Co. from $170.00 to $190.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat